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A 47-year-old woman was evaluated in the Nephrology Clinic at New
England Medical Center for autosomal dominant polycystic kidney dis-
ease (ADPKD). She had undergone abdominal and pelvic noncontrast
computed tomographic scans for the evaluation of dyspareunia and stress
incontinence. These studies revealed markedly enlarged cystic kidneys as
well as multiple cysts involving most of the liver parenchyma, particularly
the superior right lobe; the liver size was normal. Several hepatic
Structures with high attenuation values were consistent with complicated
hemorrhagic cysts or solid masses. She had questionable minimal intra-
hepatic biliary ductal dilation but no pancreatic or splenic cysts.
The patient had been unaware of her renal diagnosis prior to these
studies and referred herself for further evaluation. In the Nephrology
Clinic, she specifically denied any history of hypertension, flank or
abdominal pain, urinary tract infection, or hematuria. She was gravida 4,
para 2; she had never used oral contraceptives. The serum creatinine was
reportedly normal until one year previously, when it was 1.5 mg/dl. She
was taking no medications, and a review of systems was negative.
Her family history revealed that her mother and one sister had
end-stage renal failure due to ADPKD. A brother also had ADPKD with
hypertension and well-preserved renal function.
Physical examination disclosed a blood pressure of 120/90 mm Hg. Mild
arteriolar narrowing was present on funduscopic examination. The chest
was clear and cardiac examination was normal. The left kidney was
markedly enlarged and slightly tender to palpation. The right kidney was
not felt. The liver edge was palpable but nontender. Trace pedal edema
was present. Gynecologic examination revealed grade-2 uterovaginal
prolapse.
The serum creatinine and BUN levels were 1.7 and 28 mg/dl, respec-
tively. Hematocrit was 36%. Liver function tests, including bilirubin, LDI-I,
AST, and ALT, were within normal limits. Cholesterol was 159 mg/dl.
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Urinalysis revealed a specific gravity of 1.010; pH, 6.0; trace protein; 1+
leukocytes; 10 white blood cells/high-powered field; one degenerating cell
cast; white cell clumps; rare renal tubular cells; and few bacteria. A routine
urine culture grew mixed vaginal flora of 50,000-100,000 bacteria/mI.
In the year since the initial evaluation, the patient has remained
symptom-free. Her blood pressure has been in the normal range most of
the time, and she has received only nonpharmacologic interventions. Most
recently, the serum creatinine was 1.4 mg/dl, and the patient was eating a
mildly protein-restricted diet.
Discussion
DR. RONALD D. PERRONE (Division of Nephrology, New England
Medical Center, and Associate Professor of Medicine, Tufts Univer-
sity School of Medicine, Boston, Massachusetts, USA): Autosomal
dominant polycystic kidney disease (ADPKD) accounts for ap-
proximately 8% to 10% of individuals with end-stage renal disease
(ESRD) in the United States and Europe. Progressive expansion
of multiple, bilateral renal cysts leads to massive enlargement of
the kidneys and to progressive renal failure. Although renal cysts
and renal failure are the cardinal manifestations of ADPKD,
ADPKD is a systemic disease with multiple extrarenal manifesta-
tions encompassing both cystic involvement of other organs and
connective tissue abnormalities, The observations that only one-
half of the ADPKD population reaches ESRD by the middle of
the sixth decade [1, 2] and that dialysis survival for patients with
ADPKD surpasses that of the general dialysis population [3, 1
suggest that the extrarenal manifestations of ADPKD have ample
time to produce clinical complications. The finding of extensive
hepatic cystic disease in the patient described today emphasizes
this point; with a substantial probability of prolonged survival
even after developing ESRD, she is unlikely to remain free from
the complications of extensive hepatic cystic involvement for the
remainder of her life.
Recent advances in the molecular genetics of ADPKD include
the discovery of multiple genetic loci—PKDI on chromosome 16
[51; PKD2 on chromosome 4 [6, 7] and at least one additional site
unlinked to chromosome 4 or 16 [81—and the identification and
cloning of the PKD1 and PKD2 genes and prediction of their
protein products. Polycystin is a 4304 amino acid protein encoded
on chromosome 16 that includes an amino-terminal portion
comprising a series of extracellular protein domains present in a
combination that has not been described previously [9—11]. The
predicted sequence suggests that polycystin is a multifunctional
protein that participates in protein-protein and protein-carbohy-
drate interactions in the extracellular compartment and that it
mediates cell-cell or cell-matrix interactions. The protein product
of the PKD2 gene contains 968 amino acids and exhibits structural
similarity to polycystin and the family of voltage-activated calcium
and sodium channels [12]. Mochizuki et al have proposed that the
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PKD2 protein acts in a common signal transduction pathway with
PKD1 and other proteins and ligands [12].
These advances in our understanding of the molecular genetics
of ADPKD likely will improve the sensitivity and specificity of
diagnostic testing for ADPKD, allow correlation of clinical ex-
pression of ADPKD (phenotype) with specific mutations (geno-
type), improve our ability to develop patient-specific prognostic
information both for renal and extrarenal complications, and
allow development of rational and specific therapy. To this
purpose, let us look in detail at the extrarenal manifestations of
ADPKD and their relationship to molecular genetics.
Hepatic cysts
Hepatic cysts are the most common extrarenal manifestation of
ADPKD, with a highly variable prevalence ranging from 10% to
88% [13—17]. This variability probably is due to the increasing
prevalence of hepatic cysts with age; cysts are detectable in only
10% to 17% of patients below age 40 and 70% to 75% of patients
older than age 60 [13, 18, 19]. Hepatic cyst disease is most severe
in patients with the most severe renal cystic disease and the worst
renal function [14, 20]; hepatic cysts are found in 60% to 75% of
ADPKD patients with ESRD who are on or approaching dialysis
[20]. The prevalence of hepatic cysts in nonazotemic subjects is
similar for men and women; however, severe hepatic cystic
disease, that is, increased number and size of cysts, primarily
affects women, particularly those who have had multiple pregnan-
cies or exposure to exogenous female sex steroids [141. By contrast
to this female predominance of severe hepatic cystic disease,
females with ADPKD are not at greater risk for severe renal cystic
disease; in fact, male ADPKD patients have a faster rate of
decline in GFR than do females [211.
Both in male and female patients, liver function is well pre-
served and liver enzymes and bilirubin usually remain normal [22,
23]. The preservation of liver function in ADPKD patients with
hepatic cysts was explained by a careful study in nine women with
massive hepatic cystic disease that revealed preservation of a
normal volume of hepatic parenchyma despite a large number and
volume of cysts [23].
The potential for complications of hepatic cystic involvement in
ADPKD is significant; however, we have little population-derived
information from which to compute precise incidence and prev-
alence data. In one study of ADPKD patients with ESRD, most of
whom were on dialysis, complications of hepatic disease, including
hepatic cyst infection and malignancy, accounted for 10% mor-
tality [20]. More commonly, hepatic cysts are asymptomatic,
particularly in the predialysis patient [201. Patients with massive
hepatic cystic disease can have elevated alkaline phosphatase and
transaminase levels [24]; slightly increased portal-systemic shunt-
ing has been reported in such patients [251. A small number of
patients, mostly women, develop disabling abdominal pain and
distention secondary to massive hepatomegaly from large num-
bers and volume of hepatic cysts. Partial hepatectomy, surgical
fenestration, percutaneous drainage, or alcohol sclerosis of sev-
eral dominant cysts may be required to palliate such symptoms
[24, 26]. As a last resort, total hepatectomy and orthotopic liver
transplantation have been utilized in rare patients with disabling
symptoms, portal hypertension, or hepatic venous outflow ob-
struction due to massive cystic disease [27—29].
Fever, leukocytosis, and right upper quadrant pain are the
typical symptoms of hepatic cyst infection; however, these symp-
toms also could arise from infection of one or more renal cysts or
from more common entities such as cholecystitis or bowel perfo-
ration. Hepatic cyst infections frequently elevate the aspartate
aminotransferase, alkaline phosphatase, and/or bilirubin. Because
uncomplicated hepatic cysts usually don't elevate liver enzyme or
bilirubin levels, this finding can help distinguish hepatic from
renal cyst infection. The choice of an imaging modality for
identifying an infected hepatic cyst and distinguishing other
causes also remains unclear, as commonly available imaging
techniques have not been systematically evaluated in this patient
population. Ultrasound seems a reasonable first choice; if unsuc-
cessful, computed tomography or magnetic resonance imaging is
indicated [22]. Telenti and colleagues, using a 111indium-labeled
leukocyte scan, identified the infected cyst in all four patients in
whom it was used; 67gallium scans were positive in only one of
three patients [22]. Infection usually affects patients with massive
hepatic cystic involvement [20, 22, 30]. Hepatic cyst infections do
not respond well to antibiotics alone; in a review of their own
experience with five patients and nine others reported in the
literature, Telenti et al reported unfavorable outcomes in only one
of seven patients undergoing cyst drainage plus antibiotic therapy,
whereas six of seven patients receiving antibiotics without cyst
drainage had unfavorable outcomes [22]. Lipid-soluble antibiotics
are recommended, but little information has been published
about the penetration of antibiotics into infected hepatic cysts.
Ciprofloxacin, but not chloramphenicol, concentrates in hepatic
cysts [22].
Rare complications of massive ADPKD hepatic cystic disease
include obstructive jaundice [31—33], portal hypertension with
esophageal varices [30, 34], and obstruction of hepatic venous
outflow [29, 35]. These complications are thought to be due to
compression of biliary or vascular structures, respectively, by a
single dominant cyst or by multiple cysts. When one or several
dominant cysts can be identified as the origin of obstruction, cysts
can be decompressed via either surgical fenestration [24] or
percutaneous drainage [33] with subsequent sclerosis with alcohol
[31], Pantopaque [36], or possibly minocycline [37]. Spontaneous
obstruction of hepatic venous outflow has been noted [29], as has
obstruction following abdominal surgical procedures including
unilateral [38] or bilateral nephrectomy [29, 39] and fenestration
of hepatic cysts [40]. Magnetic resonance imaging was useful in
determining the degree of flow in the inferior vena cava, hepatic
and portal veins, and in detecting abnormal collateral veins [29].
The treatment for hepatic venous outflow obstruction is decom-
pression of the congested liver [29].
Congenital hepatic fibrosis, frequently associated with autoso-
mal recessive polycystic kidney disease, also affects a small
number of families with typical ADPKD [41], some with disease
definitively linked to the PKD1 locus on chromosome 16 [42]. The
clinical course of congenital hepatic fibrosis varies considerably
and is not inherited in an autosomal dominant fashion, in contrast
to the inheritance of renal cysts in the same families [41]. Whether
this phenomenon occurs by chance, due to modification by
interaction with other genes or environmental factors, or by
specific mutations in the PKD1 gene has not been determined.
Hepatic cysts in patients with ADPKD derive from the intra-
hepatic biliary epithelium. This conclusion is based on histomor-
phometry [43], microdissection studies [44], the pattern of cyto-
keratin expression [45], the presence of secretory IgA and
secretory component in hepatic cyst fluids [16], and functional
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evidence of secretin-induced secretion [16]. Cysts grow as the
result of progressive dilation of biliary ductules in von Meyenburg
complexes or biliary hamartomas, which eventually separate from
the ductule of origin [44, 46]. Polycystin is expressed both in
hepatocytes and in biliary epithelium during the first four years of
life. Thus, polycystin might be involved in the development of the
intrahepatic biliary tree [47].
Secretin-induced secretion by the normal intrahepatic biliary
epithelium is rich in bicarbonate [48], whereas intact ADPKD
hepatic cysts primarily secrete chloride in response to secretin
[16]. We recently have shown that anion exchange activity is
decreased in hepatic-cyst-derived epithelial cell lines from pa-
tients with ADPKD when compared with intrahepatic biliary
epithelial cell lines from normal individuals (Fig. 1) [45, 49]. This
observation, when interpreted in light of the accepted paradigm of
pancreaticobiliary secretion,1 could account for increased secre-
tion of chloride into ADPKD hepatic cysts and provide a means
for cyst expansion.
Table 1 illustrates the association of extrarenal manifestations
of ADPKD with their different genetic forms; the data for hepatic
cysts are included. Genotype was determined by linkage analysis.
Precise prevalence data are unavailable, as most ADPKD kin-
dreds have not been systematically evaluated for the presence of
extrarenal involvement. Comparisons between kindreds are also
complicated by the age-related increase in the expression of
hepatic cysts. At present I believe that hepatic cysts occur in all
known genetic forms of ADPKD, but we cannot yet determine
whether the extent of cystic involvement varies among genotypes.
Kimberling and colleagues found hepatic cysts in 43% of affected
family members in one large PKD2 kindred [6, 51]. A recent
publication demonstrated similar age-related prevalence of hep-
tatic cysts in 146 PKD1 and 20 PKD2 patients [52]. Only very
preliminary information is available regarding extrarenal manifes-
tations of ADPKD in patients with documented mutations of the
PKD1 gene. One mutation in particular recently was found to be
associated with massive hepatic cystic disease in men [53].
Isolated polycystic liver disease (that is, in the absence of renal
cysts) is a separate hereditary disorder that appears to be unre-
lated to ADPKD. Genetic linkage studies document an absence of
linkage to the known ADPKD loci on chromosomes 4 and 16 [54].
Intracranial aneurysm
Rupture of an intracranial aneurysm (ICA) is one of the
dreadest complications of ADPKD. Autopsy series, case reports,
and prospective imaging studies provide strong support for the
relationship between ICA and ADPKD [34, 55—59], but questions
remain as to the exact prevalence of ICA, the identification of
patients at high risk of rupture, and whether screening and
prophylactic repair should be performed in asymptomatic patients
with small ICAs.
The reported frequency of ICA ranges from 0% to 41%
[reviewed in Ref. 60]; this wide variation likely reflects the use of
different diagnostic techniques, selection biases in some studies
due to evaluation only of symptomatic or patients with a family
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Fig. 1. Decreased anion exchange in ADPKD liver cyst-derived epithelial cell
lines. Normal intrahepatic biliaty or ADPKD liver-cyst-derived epithelial
cell monolayers were perfused initially with physiologic HCO buffer.
After establishment of a stable baseline intracellular pIT (pH1), the
perfusate was changed to Cl-free, HCO3 buffer. Two responses were
noted. In one set of experiments, neither CL replacement with gluconate
nor reintroduction of Cl had any effect on pH (A, curve A). In a second
set of cellular monolayers alkalinized by — 0.1 pH units (B, curve B)
reintroduction of CL did not restore pH to basal levels. Normal
intrahepatic biliary epithelial cell monolayers (B) were alkalinized in
response to CL-free perfusate and rapidly acidified after reintroduction of
CL. Points are mean SE. For clarity, SE bars are shown only for every
tenth reading. (From Ref. 45 with permission).
Biliary HC03 secretion is thought to occur via exit of HC03 via an
apical CL-HC03 anion exchanger operating in parallel with an apical
CL channel, possibly the cystic fibrosis transmemhrane regulator (CFTR),
which allows Cl recycling [50].
history of ICA, differences in racial or ethnic background, and
possibly the association of ICA with particular mutations of the
PKDI or PKD2 genes that might be shared within specific
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Table 1. Molecular genetics of the extrarenal manifestations of ADPKD
Association with
ADPKD phenotype,
Genotype by linkage analysis
Unlinked to Unlinked to
Site linkage undetermined PKD1 PKD2 PKD1 PKDI or 2
Hepatic cysts Present in all surveys
of ADPKD;
increases with age
[14, 961
40%—70%
6%—90% [521
43% [6, 51]; present
[971; 0%—100% [52]
Present [98, 991;
56% [100]
Present [8]
Congenital hepatic Rare; case reports only Present [42]
fibrosis [41, 1011
Colonic diverticuli 40%—80%; surveys
Cardiac valvular 0%—30%; surveys
abnormalities
Intracranial aneurysms 4%—40%; retrospective
and prospective
surveys
Present [70] Present [6, 51, 1 02]
Thoracic and abdominal Unknown; likely 1 Kindred [103]
aortic aneurysms kindred specific
Intracranial arterial 2% [77]
dolichoectasia
Coronary artery Rare; case reports
aneurysms
Ovarian cysts Unknown; case reports Present [8]
Testicular cysts Unknown; case reports
Seminal vesicle cysts Unknown; case reports
Arachnoid cysts 5%—8% [104]
Pineal cysts Unknown; case reports
Splenic cysts Unknown; case reports
Pancreatic cysts 5%—10%; surveys [96] 4% [52] Absent [52] Present [8]
Bladder cysts
aNumbers in brackets re
Unknown; case reports
fer to references.
kindreds. The latter speculation is supported by the observation
that ICAs tend to cluster within families [57]. Most ICAs occur in
the anterior circulation [611. Recent prospective imaging studies
of asymptomatic subjects using high-resolution computerized
tomographic or magnetic resonance imaging techniques with or
without four-vessel cerebral angiography found ICAs in 0% to
11% of subjects (Table 2); all ICAs found in these studies were
less than 7 mm in size (Fig. 2) [56—59].
Intracranial aneurysm produces symptoms via three mecha-
nisms: compression of adjacent structures, focal brain ischemia
due to embolism, and subarachnoid hemorrhage due to rupture.
Urgent neurologic or neurosurgical consultation should be ob-
tained for ADPKD patients with any new, severe, or focal
neurologic symptoms, including headache. Rupture of an ICA is
a catastrophic event, with mortality approaching 50% and devas-
tating morbidity affecting 50% of the survivors. Kaehny and
Everson suggested that patients with ADPKD have a greater
mortality rate from ICA rupture because of a greater prevalence
of renal insufficiency and hypertension than do patients without
ADPKD [34]; however, when data derived from post-mortem
studies are excluded, the mortality rate is similar to that in the
population without ADPKD [61]. Intracranial aneurysms rupture
at an earlier age in patients with ADPKD. Of reported ruptured
ICAs in patients with ADPKD, 64% to 80% occurred before age
50, whereas in patients without ADPKD, rupture of ICAs oc-
curred in only 40% to 45% before age 50 [61]. Neurosurgical
intervention for ruptured ICA is done primarily to prevent
recurrence of bleeding; few patients require evacuation of a
space-occupying hematoma to improve outcome. Rupture of an
ICA is only one of multiple diagnostic possibilities that must be
considered when evaluating an acute neurologic event in a patient
with ADPKD. Much more likely are cerebral complications due to
hypertensive cerebral hemorrhage or cerebral ischemia and in-
farction [62, 63].
The catastrophic outcome of ruptured ICA has prompted
extensive discussion of the risks and benefits of screening and
prophylactic repair of ICA in asymptomatic patients with AD-
PKD. Levey et al formally examined this question using decision
analysis [551. Their analysis, using the baseline assumptions shown
in Table 3, suggested that screening and prophylactic repair only
increased life expectancy for patients younger than age 25. These
authors acknowledged that their baseline estimate of prevalence,
30%, was likely an overestimate; more recent data from large
prospective studies suggest that the prevalence of aneurysm in
asymptomatic patients with ADPKD is less than 10% (Table 2).
The prevalence of asymptomatic ICA is 22% to 25% in family
members of ADPKD patients who are known to have ICA. More
recent estimates of surgical morbidity and mortality suggest a
figure of 2% to 6%, rather than the 1% to 3% figure utilized in the
initial analysis. These modified figures were encompassed in the
sensitivity analyses provided in the original study; their incorpo-
ration strengthens the argument against angiographic screening
for the unselected ADPKD population. If, on the other hand, a
highly sensitive and specific noninvasive screening test (greater
than 80% and 85%, respectively) could define an individual
ADPKD patient with a high probability of having an ICA,
angiographic study and prophylactic repair of the lesion would
confer a significant survival benefit [55]. Magnetic resonance
angiography (MRA) with time-of-flight image processing tech-
niques probably meets these criteria, particularly for aneurysms
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Fig. 2. Stability of small intracranial aneurysm in
ADPKD. Serial 3-dimensional time-of-flight
magnetic resonance angiographic images of a
1.5 mm basilar tip aneurysm in a 45-year-old
woman with ADPKD. There was no growth or
de-novo aneurysm formation over an interval of
51 months. (From Ref. 72 with permission).
Table 2. Prevalence of intracranial aneurysms (ICA) in asymptomatic ADPKD patients by noninvasive screening methods
Confirmation
Modality
Number
of patients Definite ICA Indeterminate
by 4-vessel
arteriogram Reference
High resolution I CT or MR scan 96 0 11 (<4 mm) 0/2 had ICA Torres et al [561
with 3 mm cuts
High resolution I CT scan 71 0 11 suspicious 2/7 had ICA; 5/7 had vascular Chapman et al [59]
with 2 mm cuts structures that matched
suspicious areas on CT
MRI and MRA with 3-dimensional 85 9 (11%); all less than 0 Not done Huston et al [72j
time-of-flight and phase contrast 6.5 mm
techniques
MRI and MRA with 3-dimensional 93 13 ICA in 10 patients 0 8/8 ICA confirmed (6 Ruggieri et al [571
time-of-flight techniques (11%); all less than
7 mm
patients)
larger than 5 mm [64, 65]. It is extremely important to note that
the positive predictive value of even very highly sensitive and
specific screening tests is powerfully affected by the prevalence of
ICA (Fig. 3). Using estimates of 90% sensitivity and specificity, a
population prevalence of 10% yields a positive predictive value of
50%. In other words, approximately 20% of all ADPKD patients
screened would be defined as having ICA; arteriography would
reveal an ICA in only one-half of this group. If the population
prevalence were 30% (that is, a positive family history of IcA),
the positive predictive value of an MRA showing an ICA is 80%;
therefore, in most patients with family histories of ICA who have
a positive MRA, angiography would reveal an ICA. But patients
with ADPKD appear to have an increased rate of neurologic
complications due to cerebral angiography, so it is highly desirable
to limit the number of studies [59].
At present, no neurosurgical consensus exists on the appropri-
ate treatment for small, asymptomatic KAs (less than 10 mm).
Data derived from the general population indicate that the main
predictor of aneurysmal rupture is its size [66, 67]. Wiebers and
Torres advocate repeated MRA screening of known asymptom-
atic, small ICAs [65]. They base their recommendation on data
showing that there were no ruptures of 102 ICAs less than 10 mm
in diameter over a mean followup period of eight years [68].
Juvela et al advocate prophylactic repair of any surgically acces-
sible ICA, as long as the age and concurrent diseases of that
patient do not increase the surgical risk [67]. Three studies clearly
document the formation and rupture of de-novo ICA in ADPKD
patients with prior ICA rupture [55, 69-71]. Data on long-term
followup of known incidental (discovered solely via screening)
ICA in patients with ADPKD are very limited. In a recent study
of 18 ADPKD patients, 15 asymptomatic, small (1.5—6.5 mm)
ICAs were followed for a mean of 33 months using serial MRA
examinations [72]; none of the aneurysms changed in size or
ruptured, and no de-novo aneurysms formed. One patient had
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Table 3. Decision model revisited: screening for occult intracranial aneuiysms in ADPKD
Posterior probability
Original estimate based on positive
from Levey et al, Present estimate for MRA in an
JVEJM, 1983 ADPKD population individual patient
Probability of aneurysm 30% <10% 70%
Anterior circulation, unilateral (1 or more) 80% 80%
Anterior circulation, bilateral 10% 10%
Posterior circulation 10% 10%
Annual probability of rupture 2% (no adjustment
for size of
aneurysm)
1%—2% Unknown; dependent
on size
Grave complication of rupture 37% 50%—60% 50%—60%
Grave surgical complication — 6% 6%
Anterior circulation, unilateral 1%
Anterior circulation, bilateral 2%
Posterior circulation 3%
multiple aneurysms; this frequency is consistent with that reported
in other studies of ICA or subarachnoid hemorrhage in patients
with ADPKD (14% to 31%) and in the general population (19%
to 34%) [reviewed in Ref. 721. Although the results from this
study should be considered preliminary, they do suggest that the
rate of development of de-novo aneurysms and the frequency of
multiple aneurysms are similar to those seen in patients with
sporadic ICA in the non-ADPKD population.
The lack of information on the natural history of ICA in
patients with ADPKD has precluded the development of defini-
tive recommendations for screening for asymptomatic ICA in this
group. Nonetheless, it appears reasonable to screen with MRA
those ADPKD patients with a history of ruptured ICA, those with
a family history of ICA or subarachnoid hemorrhage, those with
high-risk occupations (such as airline pilots), those planning to
undergo major elective surgery that could affect cerebral hemo-
dynamics, and those who need the reassurance of a negative study
[61]. The benefits of screening are very limited in patients already
on dialysis because of their reduced life expectancy [731; ADPKD
patients with ESRD who have no symptoms suggestive of ICA
should not be screened.
Intracranial aneurysms are associated with all known genetic
forms of ADPKD (Table 1); the precise prevalence is unknown.
The expression of polycystin in myocytes of elastic and large
distributive arteries [74] suggests a pathophysiologic basis for ICA
in ADPKD. Only preliminary information has associated specific
mutations of polycystin with ICA [53]; familial clustering suggests
that such an association might exist.
Other vascular abnormalities have been reported in patients
with ADPKD, including thoracic, iliac, and abdominal aortic
aneurysms [60, 751; coronary artery aneurysms [76]; intracranial
arterial dolichoectasia (elongation and dilation of an arterial
segment) [77]; intracranial arterial dissection [781; and megadoli-
chobasilar artery [75]. These entities are uncommon and their
prevalence unknown, except for intracranial arterial dolichoecta-
sia, found in 2% of ADPKD patients and associated with arterial
dissection [77].
Cardiac disease
Since the initial report of Leier et al in 1984 [79], cardiovascular
abnormalities, including mitral and aortic valvular prolapse and
regurgitation and annuloaortic ectasia [80], have been considered
important extrarenal manifestations of ADPKD. However, pro-
spective evaluation of ADPKD patients has shown a highly
variable prevalence of these abnormalities, ranging from their
absence to involvement of almost one-third of the ADPKD
population (Table 4). In the majority of reported cases, valvular
regurgitation is hemodynamically inconsequential. The preva-
lence of left-ventricular hypertrophy in normotensive patients
with ADPKD also varies (Table 4). Although polycystin is ex-
pressed in normal fetal and childhood myocardium [47], its
relationship to valvular heart disease and left-ventricular hyper-
trophy remains to be determined.
In several studies, the unaffected family members of ADPKD
patients have exhibited an excessive prevalence of mitral and
aortic valvular prolapse and regurgitation in comparison to unre-
lated control subjects, but not to the same extent as ADPKD
patients [81, 821. The basis for this increase has not been
determined; differences in study design, methodology, or genetic
background could account for it. Histologic examination of mitral
and aortic valve tissue from ADPKD patients with severe valvular
heart disease showed loss and disruption of collagen with myxo-
matous degeneration [79].
The natural history of cardiac valvular prolapse and regurgita-
tion in ADPKD is not known, but nothing suggests that these
lesions behave differently than those seen in the general popula-
tion without ADPKD. Prophylaxis for bacterial endocarditis is
indicated in the presence of valvular regurgitation but not for
valvular prolapse without regurgitation [83].
Diverticular disease
Both an increased prevalence of diverticulosis and an increased
risk of complications from complicated diverticular disease are
features of ADPKD [60]. However, few systematic studies of
diverticular disease in ADPKD have emerged, and not all studies
report an increased prevalence. Scheff and colleagues found the
prevalence of diverticulosis to be 83% in ADPKD patients on
hemodialysis versus 32% of controls with chronic renal failure and
38% of age- and gender-matched controls [841. An autopsy series
in Olmstead County, Minnesota, detected a 40% prevalence of
diverticulosis in patients with ADPKD, a rate thought to exceed
that in the general population [85]. Kupin et al found a 30%
prevalence of diverticulosis in ADPKD patients with chronic renal
failure versus 28% in age- and gender-matched controls with
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Extrarenal manifestations of ADPKD in children
In general, children with ADPKD have the usual renal mani-
festations but few extrarenal manifestations. Hepatic cysts were
found in one patient by biopsy at age 8 months and by comput-
erized tomography at 6 years; computerized tomography revealed
pancreatic cysts in this same patient at age 16 [89]. One girl with
ADPKD died of a ruptured ICA at age 12 [90]. Echocardio-
graphic screening of 86 children with ADPKD revealed mitral
valve prolapse in 12% versus only 3% of their unaffected siblings
[91]. Hypertensive children with ADPKD had a greater left-
ventricular mass index than did their unaffected siblings [91].
___________________________________
Impact on mortality
Prevalence
Fig. 3. Predictive value of positive screening test. The impact of disease
prevalence (prior probability) on the proportion of patients with a positive
test who actually have disease is modeled as a function of different levels
of sensitivity and specificity. Arrows indicate maximum estimates for
prevalence of intracranial aneurysm in ADPKD patients without a family
history of intracranial aneurysm (10%) and in ADPKD patients with a
family history of intracranial aneurysm (30%). Note that even for a highly
sensitive and specific test, a low prevalence of the underlying disorder
results in a substantial number of false-positive studies. Sensitivity!
specificity symbols are: (—) 80/80; ( ) 90/90; (- - - -) 70/90; (— — —)
100/100.
chronic renal failure [86]. Chart review detected a 4% prevalence
of symptomatic diverticular disease in the Toronto ADPKD
population [87]. The rate of complications from diverticular
disease in patients with ADPKD is increased, and deaths from
complications of diverticulosis are overrepresented, in the pa-
tients with ADPKD who have received renal transplants [34, 60,
86].
Diverticulitis and colonic perforation, both serious complica-
tions of diverticular disease, require early and specific interven-
tion, possibly including surgety when medical management fails.
Early recognition in ADPKD patients can be problematic because
diverticulitis is easily confused with other causes of abdominal
pain and fever, including infection, hemorrhage, and rupture of
renal and hepatic cysts. Not surprisingly, diverticulitis is managed
similarly in the ADPKD and non-ADPKD populations.
It is not known whether diverticular disease in patients with
ADPKD results from abnormal PKD gene expression or from
nongenetic factors such as increased intra-abdominal pressure.
Polycystin is expressed in cells at the base of intestinal crypts but
the relationship, if any, of this finding to the formation of
diverticuli remains to be determined [47].
Pregnancy and extrarenal manifestations of ADPKD
A large study of pregnancy in ADPKD (605 ADPKD patients
and 244 unaffected family members) revealed no complications
related to extrarenal manifestations such as ICA, cardiac disease,
or hepatic cysts [88]. The vast majority of women in this study had
normal serum creatinine levels prior to pregnancy. Fertility rates
were similar in men and women with ADPKD; the incidence of
ectopic pregnancy was increased in women with ADPKD but not
to a significant degree [88].
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0.0 0.2 0.4 0.6 0.8 1.0 Clearly, the extrarenal manifestations of ADPKD contribute
significantly to morbidity. Yet patients with ADPKD have better
survival rates on dialysis than do general dialysis patients [3, 4].
This observation appears counterintuitive in view of the large
number of extrarenal manifestations affecting primarily the car-
diovascular and gastrointestinal systems. Review of the limited
data available suggests that mortality in ADPKD patients is
primarily due to infectious and cardiovascular complications,
extrarenal abnormalities contributing less to mortality. Fick et al
have carefully evaluated causes of death in ADPKD [92]. Prior to
1975, the major causes of death in patients with ADPKD were
infection (30%), uremia (28%), and cardiac disease (21%). With
the widespread availability of dialysis after 1975, cardiac disease
accounted for 36%, and infection for 24%, of deaths [92]. Most
patients who died of cardiac causes had myocardial infarction or
congestive heart failure [92]. In no case did cardiac valvular
abnormalities contribute to death. Another large series only
documented one cardiac-valve-related death out of 24 deaths
among 228 ADPKD patients over a 10-year study period [82].
Infection—primarily sepsis—was equally prevalent before and
after 1975; 47% of deaths due to infection were directly related to
ADPKD (including four deaths due to diverticulitis); only 3
deaths from infection were related to dialysis access [92]. Neuro-
logic causes accounted for 12% of deaths; one-half of these
resulted from ruptured ICA. No deaths were associated with the
complications of hepatic cystic disease; by contrast, another
retrospective study reported that 10% of deaths in ADPKD
patients on or near dialysis were due to hepatic cyst infection or
cholangiocarcinoma [20]. Other retrospective studies confirm that
cardiovascular disease, primarily coronary artery disease, and
infections are the leading causes of death in the ADPKD popu-
lation receiving renal replacement therapy [4, 87, 93—95].
In my discussion, 1 have attempted to review the principal
extrarenal manifestations of ADPKD, including their diagnosis,
management, and relationship to molecular genetics. Despite the
multiplicity of extrarenal manifestations, long-term survival of
ADPKD patients with ESRD is better than that of nondiabetic
patients of comparable age. Many important issues remain to be
clarified, including the definition of the natural history of these
disorders, the relationship to specific mutations of the known
ADPKD genes, and the development of effective strategies for
screening, diagnosis, and early intervention. To this end, I suggest
that careful characterization and long-term followup of the extra-
renal manifestations of ADPKD be performed in parallel with
studies of molecular genetics. The goal of these efforts should be
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to determine whether a relationship exists between specific mu-
tations and clinical phenotypes and, ultimately, to develop strat-
egies for effective clinical intervention.
Questions and answers
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): What proteins do the ADPKD
genes make, and specifically, what do those proteins do? I'm
particularly interested in the relationship between the proteins
and extracellular matrix formation.
DR. PERR0NE: The protein made by the gene for PKDI has
been designated polycystin [9—Il]. Its function is unknown. Be-
cause of its large putative extracellular component and the
presence of a number of domains or small areas of protein
sequence that are similar to other proteins with known functions,
it has been predicted that polycystin participates in cell-cell and
cell-extracellular matrix contacts by virtue of protein-protein and
protein-carbohydrate interaction.
The protein encoded by the PKD2 gene [12] has not been
named yet; it exhibits homology to PKDI and to the family of
voltage-gated calcium-channel and sodium-channel proteins. Its
function also remains to be determined.
DR. HARRINGTON: Even with our current limited information,
can we tie the abnormal genes and abnormal proteins to the
production of cysts? Is the problem with the pumps, or is it with
the basement membrane that allows the cysts to form?
DR. PERRONE: There are three essential criteria for cyst forma-
tion: (1) cell proliferation; (2) abnormal basement membranes;
and (3) secretion of fluid into the cyst. All these processes have
been well documented in human PKD, animal models, and
cellular models of cystic disease. Cysts in the kidney and the liver
begin as isolated diverticulae of the nonobstructed tubule or the
bile duct. They progressively enlarge and separate from their
tubule or duct of origin. It's possible that these cells interact
abnormally with the extracellular matrix. Once cysts are separated
from the tubule of origin, they enlarge by secretion of fluid into
the cyst. The putative structure of polycystin would support the
hypothesis that abnormal cell-cell and/or cell-extracellular matrix
interactions initiate and sustain cyst formation and growth. Of
interest, the bile duct is another site of expression of polycystin
[471.
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston): Can you tell us more about the
mechanism of fluid secretion into hepatic cysts?
DR. PERRONE: As you know, this area has been a focus of study
for me and my collaborators, Drs. Douglas Jefferson and Shelley
Grubman. Secretion of bicarbonate by the normal intrahepatic
biliaiy epithelium is thought to involve the apical exit of bicar-
bonate via a chloride-bicarbonate anion exchanger operating in
parallel with an apical chloride channel, possibly the cystic fibrosis
transmembrane regulator (CFTR) [50], which allows chloride to
recycle across the apical membrane. Intact ADPKD liver cysts
secrete primarily chloride rather than bicarbonate in response to
secretin [161. We have reported that epithelial cells derived from
ADPKD liver cysts have decreased anion exchanger function,
possibly because of impaired membrane localization [45, 49]. We
have speculated that liver cyst secretion in ADPKD occurs via
CFTR, as for ADPKD renal cysts, and is associated with down-
regulation of the anion exchanger. In renal cysts, data suggest that
fluid is secreted as a result of cyclic-AMP-stimulated chloride
secretion into the lumen of the cyst via CFTR [110]. Grantham
and coworkers also have identified autocrine substances in cyst
fluid that activate cyclic AMP and cause fluid secretion [ill].
DR. HARRINGTON: Early in your talk, you mentioned that
secretin stimulates fluid formation both in hepatic and renal cysts.
Does that observation give us any clues as to the mechanism of the
cystic fluid production?
DR. PERRONE: The stimulation of fluid secretion into a renal
cyst by secretin has been reported only for one renal cyst [16].
Thus, this observation must be interpreted with caution. Secretin
acts via cyclic AMP, so it suggests the possibility of a similar
mechanism. Some patients with liver cysts have postprandial pain;
perhaps secretin causes this pain by stimulating cyst fluid secre-
tion.
DR. MAIIAs: You mentioned that a very small number of
mutations of the PKD1 gene have been described so far. Is any
information available on the association of any one of these
mutations with a specific phenotype, namely, type or severity of
extrarenal disease?
DR. PERRONE: The only well-documented genotype/phenotype
correlation that I'm aware of is in patients with deletions of large
portions of chromosome 16 encompassing both the tuberous
sclerosis (TSC2) and the PKDI loci [112]. These patients have
tuberous sclerosis with very severe autosomal dominant polycystic
kidney disease that presents in infancy. Recent preliminary data
from Gabow et a! suggest an association between several pheno-
typic manifestations of ADPKD, including very early onset renal
cyst disease, severe liver cyst involvement in men, and intracranial
aneurysms with particular mutations of PKD1 [53]. Clearly,
identification of clinical phenotypes associated with particular
mutations will enable better targeting of diagnostic and therapeu-
tic modalities.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center): In the therapy of this disease, is there any role for
an "exorcyst?" Prominent cyst formation occurs in both the liver
and kidney; however, only the kidney loses function. Although
both these organs are encapsulated, the liver is partially perfused
by low-pressure vessels, whereas the kidney is not. Are there any
data regarding the possible role of pressure within the cyst as a
factor contributing to renal damage?
DR. PERRONE: I'm not aware of systematic pressure measure-
ments in hepatic cysts. If you puncture a hepatic cyst even after it's
been sitting on wet ice for 24 hours, the fluid squirts out,
suggesting that the cyst is under high pressure.
DR. KING: Would you speculate why the kidney sustains damage
and the liver does not?
DR. PERRONE: As you're probably aware, in cystic kidneys the
non-cystic epithelium has a fair degree of apoptosis both in human
disease and animal models [113]. These cells undergo pro-
grammed cell death at a higher rate than normal. It would be
interesting to evaluate whether apoptosis is also occurring in the
hepatic parenchyma. Perhaps less apoptosis accounts for preser-
vation of the hepatic parenchyma in ADPKD. That's pure spec-
ulation.
DR. KING: My second question relates to the role of blood
pressure control. The MDRD study found that lowering blood
pressure below standard goals did not change the progression of
polycystic kidney disease. Given the risk of cerebral aneurysm, do
you think the blood pressure goal for patients with autosomal
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Table 4. Cardiac disease in ADPKD
Ivy [91] Zeier [105]
-
Saggar-Malik [106] Hossack 181] Timio [82] Leier [79]
Patients Children Children and young Adults Adults All ages Adults
(PKD, NPKD, CON) (86, 58, ND) adults (24, ND, 24) (14, ND, 14) (163, 130, 100) (228, 146, 181) (11, ND, ND)
Lesion
Mitral prolapse 12%, 3% ND none 26%, 14%, 2% 25%, 20%, 2% 9%
Mitral regurgitation none ND none 31%, 14%, 9% 30%, 18%, 8% 27%
Left-ventricular borderline, 10—30% increase in left 23% increase in 18%, 8%, 3% 24%, 14%, 6% 50%
hypertrophy associated with
elevated BP
ventricular mass
index in ADPKD
left ventricular
mass index in
ADPKD
Tricuspid prolapse 4% vs. 0% ND none 6%, 2%, 0% 5%, 4%, 1% none
Tricuspid none ND none 15%, 7%, 4% none none
regurgitation
Aortic dilation none Increased aortic
diameter in ADPKD
none none none 64%
Aortic regurgitation none ND none 8%, 3%, 1% 19%, 17%, 5% 100%
36% bicuspid
valve
The number of patients is listed in parentheses for each group studied. PKD: ADPKD patients; NPKD: unaffected family members of ADPKD
patients; CON: unrelated control subjects. ND: not determined, none: not found.
dominant polycystic kidney disease should differ from that recom-
mended by the Joint National Committee on Detection, Evalua-
tion and Treatment of High Blood Pressure?
DR. PERRONE: The limited data in the PKD and the non-PKD
population with aneurysms have demonstrated that one needn't
be hypertensive to develop an aneurysm. Furthermore, the pres-
ence of hypertension is not predictive of the development of an
aneurysm. However, if an aneurysm ruptures and hypertension is
present, morbidity and mortality rates are increased substantially
[68]. There is an interesting vignette from Chauveau et al [70]. A
pair of hypertensive, monozygotic, male twins had PKD and were
followed until age 47 when MRI screening for intracranial aneu-
rysm was done. One twin had taken antihypertensive medication
for 20 years. The other twin hadn't taken antihypertensive medi-
cation and had two intracranial aneurysms; the twin who took the
antihypertensive medication had none. That's intriguing, but it's
not proof of a role for hypertension in promoting aneurysmal
enlargement. I would lower blood pressure to at least less than
140/90 mm Hg, assuming that the patient tolerates it well. There
is no evidence suggesting that treating hypertension more aggres-
sively in patients with ADPKD confers any benefit. Patients
should be reminded that smoking and possibly hypercholesterol-
emia are potentially correctable risk factors for aneurysmal rup-
ture.
DR. AJAY K. SINGH (Division of Nephrology, New England
Medical Center): You presented data from Fick and coworkers
showing a relatively high mortality rate from infections in patients
with polycystic kidney disease [92]. Could you comment on those
data and on your treatment strategies with respect to renal and
hepatic cyst infections?
DR. PERRONE: These data were collected over a long period,
encompassing patients from 1956 through the initiation of dialysis
in the early 1970s until 1993. I'm not sure to what degree these
data represent current practice. As far as renal cyst infections are
concerned, accepted treatment includes lipid-soluble antibiotics,
reserving cyst drainage for the patient who responds poorly to
antibiotics. On the other hand, the limited information available
in patients with hepatic cyst infection suggests that one should
aggressively drain the infected cyst(s) [22]. Not all lipophilic
antibiotics penetrate hepatic cysts. The biliary epithelium is a
secretory epithelium, so the clinician should choose an antibiotic
that is secreted by the bile duct such as ciprofloxacin or tn-
methoprim-sulfamethoxazole. For example, chloramphenicol,
which accumulates in renal cyst fluid, does not accumulate in
hepatic cysts [22].
DR. SINGH: Given the breathtaking progress on the genetics of
polycystic kidney disease, what do you see as the future of
prenatal diagnosis of PKD and the role of genetic counseling?
DR. PERRONE: The main caveat about genetic counseling in
PKD patients is that many of them would accept the counseling
and even the prenatal diagnosis but would not act on the finding
of ADPKD in the fetus [114]. They might act on it, however, if
they really understood that the fetus had a severe disease. One
must also recall, when providing genetic and clinical counseling,
that the clinical course of the disease is extremely variable.
Statistically, about 50% of these patients will have no major
complications in a normal life span. For instance, the patient
discussed today was 47 years old and didn't have any complica-
tions related to PKD for most of her life; even at present she has
no symptoms. The upshot of this information is that most patients
with ADPKD don't believe that they have a disease severe enough
for them to avoid having children. It thus is difficult to vigorously
advocate abortion in this setting.
DR. LAWRENCE MILNER (Division of Pediatric Nephrology, New
England Medical Center): I'm intrigued about the occurrence of
hepatic fibrosis in some of the patients with ADPKD, primarily
because that's an important feature of the autosomal recessive
variety we see in our practice. Do you think a common mechanism
explains the hepatic fibrosis in these different varieties of polycys-
tic kidney disease? How do you think that the development of
hepatic fibrosis is linked to your finding of abnormal chloride-
bicarbonate exchange in ADPKD liver cyst epithelium?
DR. PERRONE: The liver in congenital hepatic fibrosis is char-
acterized by broad bands of collagenous tissue with irregular
periportal fibrosis and bile duct proliferation, and by portal vein
hypoplasia [42]. This histology is not commonly found in polycys-
tic liver disease. At least one of the families with congenital
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Table 4. Continued
Varnero Castiglioni [1081 Harrap [1091 Ritz [41
Adults Adults Young adults Adults
(21, 34, 36) (25, 18, ND) (19, 20, ND) (58, ND, 58)
33%, 24%, 3% 16%, 0 16%, 30%, trivial none
19%, 0, 0 20%, 22%, trivial none 17%, 29%
none none none Similar to controls
in the absence
of valvular
disease
12%, 0, 0 none none none
none 16%, 38% none none
none none none none
14%, 0, 3% 4%, 11% none 5%, 0
hepatic fibrosis has been documented to be linked to PKD1 [42].
The interesting point is that the hepatic fibrosis was not inherited
in that family in a dominant fashion. Whether this was an
environmental influence, good luck, or modifying genes is unclear.
The question of linkage of hepatic fibrosis to mutations of the
PKD genes is a very important area. One would speculate that
mutations in a protein that interacts with the extracellular envi-
ronment could induce changes in that environment. Possibly, a
specific mutation could induce hepatic fibrosis. Murray and
coworkers published a study demonstrating that metalloprotein-
ases, enzymes that degrade type-IV collagen, are secreted vigor-
ously by polycystic biliary epithelial cells [1151. This observation
suggests active remodeling of the extracellular matrix.
In regard to your question about the possible linkage of hepatic
fibrosis and abnormal secretion, I would say that there appears to
be no such linkage. We have found decreased chloride-bicarbon-
ate exchange in four of four different patients' hepatic cyst
epithelia, whereas hepatic fibrosis is extremely uncommon in
ADPKD.
DR. HARRINGTON: I would like to ask Dr. Linshaw two ques-
tions. How does the childhood variant of autosomal dominant
polycystic kidney disease show up in children? Do extrarenal
manifestations in children differ from those in adults with
ADPKD?
DR. MICHAEL LINsIlAw (Chief Division of Pediatric Nephrology,
New England Medical Center): Occasionally we do see infants and
very young children with autosomal dominant polycystic kidney
disease. These children are now identified earlier because of
improvements in ultrasonographic technique. Such children can
present in utero or early in life with large cysts in both kidneys, or
even in one kidney. The large cysts differentiate these patients
from those with autosomal recessive polycystic kidney disease, in
which the kidneys are huge and the cysts aren't discernible as
discrete cysts. These children often are asymptomatic initially, but
they can have or later develop abdominal masses, hypertension, or
urinary abnormalities, such as hematuria or proteinuria. Symp-
toms such as flank or back pain seem to relate to the severity of
disease and the number of cysts. The number of cysts and
frequency of cyst-related pain increase during childhood, and
hypertension also seems to occur more with increasing age, but
generally filtration rate and overall renal function do not deteri-
orate.
To answer your second question, extrarenal manifestations
don't seem to be nearly as common in children as in adults. Cysts
of the liver, pancreas, or ovaries are rare in children but have been
reported. Congenital hepatic fibrosis is more typical of autosomal
recessive PKD, but it has occurred in patients with autosomal
dominant PKD. Inguinal hernias requiring surgery might be more
common, but solid data do not exist. Abnormalities of heart valves
occur; mitral valve prolapse is significantly more common in
children with ADPKD. We worry about the development and
rupture of intracranial aneurysms in children, but luckily this is
not very common. The problem is more worrisome in families
with a history of aneurysm. In view of the morbidity of this
problem, do you or Dr. Perrone have any guidelines or recom-
mendations for the frequency and extent to which you look for
intracranial aneurysms in children? That is, in a child with
ADPKD and a family history of cerebral aneurysm, how aggres-
sively would you search for one?
DR. PERRONE: Aneurysmal rupture in children with ADPKD is
very rare. In one large series, only 7 of 71 aneurysmal ruptures
occurred in ADPKD patients below the age of 21; the youngest of
these patients was 15 [70]. In another large series, none of 35
ADPKD patients with symptomatic ICA were below age 20 [61].
There have been no studies of screening for intracranial aneurysm
in children with ADPKD. Recommendations for the frequency of
screening in adults range from only once (if negative) [551 to every
3 to 5 years [62, 72]. At present, magnetic resonance angiography
appears to be the preferred screening procedure. Based on the
earliest angiographically documented appearance of a de-novo
aneurysm in an ADPKD patient with prior intracranial aneurysm
(4.1 years earlier) [71], it appears reasonable to screen adults with
a history of an intracranial aneurysm rupture or family history of
intracranial aneurysm at an interval of 3 to 5 years. It also seems
reasonable to screen high-risk children with magnetic resonance
angiography initially and to rescreen them at the same 3- to 5-year
interval as adults.
At present, no firm data indicate the age at which screening
with magnetic resonance angiography should be initiated [116].
Decision analysis predicts that younger ADPKD patients would
derive the most benefit (greatest gain in life expectancy) from
angiographic screening for intracranial aneurysm [55]; since MRA
is virtually risk-free and highly sensitive and specific, the only
downside of screening is the high cost and low yield due to the low
prevalence rate. Finally, after an intracranial aneurysm is demon-
strated, one should remember that no consensus exists among
surgeons regarding therapy for ICA. Unfortunately, we have few
firm answers for these very complex issues, but we can hope that
molecular analysis of the different mutations of the genes for
PKD1 and PKD2 will shed light on which patients will benefit
most from repeated screening with magnetic resonance angiogra-
phy or other modalities.
DR. BERTRAND KNEBELMANN (Renal Division, Beth Israel Hos-
pital, Boston): Peter Harris' group in England showed that renal
cysts from several patients expressed an increased level of poly-
cystin messenger RNA and protein [117]. This finding could mean
that overexpression of polycystin has a toxic effect. On the other
hand, as you mentioned earlier, large deletion of one PKD1 allele,
along with the adjacent TSC2, leads to very severe disease. How
can you reconcile these observations?
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DR. PERRONE: The investigators who reported the cases of
severe infantile ADPKD due to deletion of one PKD1allele along
with the adjacent TSC2 demonstrated that these large deletions
completely inactivated PKDJ [112]. These findings contrast with
prior studies of adult ADPKD, in which abnormal transcripts
were still present [9—11]. To my knowledge, no information exists
about the expression of polycystin in renal tissue from these
severely affected children. Renal expression of polycystin has been
reported in patients with several well-characterized mutations of
the PKDI gene, including a deletion mutation (0X1330) that
removed the exons to which antibodies and mRNA assays were
directed [117]. Expression of polycystin in renal cyst epithelium
from a patient with the OXI 330 mutation was increased to levels
similar to that found in other ADPKD kidneys. Messenger RNA
levels approximated that found in normal kidney but were con-
sidered elevated, as only the product of the normal allele was
being detected. Ward et al speculated that the PKDI gene
controls its own expression via a negative-feedback loop [117].
These results require further validation with antibodies that have
been definitively demonstrated to react with polycystin.
The mechanisms by which mutant PKD1 leads to cystogenesis
are unknown at present. Recent preliminary studies suggest that
individual cysts are monoclonal and arise as the result of a second
mutation or "hit" affecting the normal haplotype in somatic
tissues, for example, kidney [118]. The mechanism of somatic
mutation in ADPKD remains to be defined.
DR. MADIAS: Why do estrogens exacerbate polycystic liver
disease?
DR. PERRONE: Women have more hepatic adenomas, solitary
hepatic cysts, and choledochal cysts than men do [14, 1191. The
reason for worse polycystic liver disease in women with polycystic
kidney disease is not known. It's interesting because men have a
faster rate of progression of renal failure and also enter dialysis at
earlier ages than women.
DR. MADIAS: Should women with ADPKD who are planning to
become pregnant be screened for cerebral aneurysms?
DR. PERRONE: The Denver group reported a very large series of
women with ADPKD and well-preserved renal function followed
through pregnancy [88]. These women had no extrarenal mani-
festations, including symptomatic ICA, or hepatic cyst problems
during 605 pregnancies. Although these data are reassuring with
regard to the paucity of extrarenal complications of ADPKD
during pregnancy, the issue of screening for ICA in young women
of child-bearing potential who have ADPKD and a family history
of ICA remains unsettled.
DR. HARRINGTON: You mentioned that patients with polycystic
kidney disease fare better on dialysis than do patients with
nondiabetic renal disease. That finding is counterintuitive, given
all the extrarenal problems in patients with polycystic kidney
disease. Is it a real difference? If so, what factors account for the
difference in outcome?
DR. PERRONE: The better survival of ADPKD patients on
dialysis versus the non-ADPKD population is generally accepted
F1 Factors that have been postulated but not proven to account
for better survival of ADPKD patients on dialysis include better
preservation of residual renal function, less severe hypertension,
and lesser degrees of anemia (at least in the pre-erythropoietin
era) [4].
In my review of the causes of death in PKD, I tried to
emphasize the point that I didn't see a major contribution to
mortality of the extrarenal complications of ADPKD. The natural
history of many of these problems, particularly cardiac valvular
abnormalities, remains to be defined.
DR. JULIA R. NEURINGER (Division of Nephrology, New England
Medical Center): I have a question relating to transplantation. It's
frustrating in clinic when we're doing transplant evaluations for
patients with PKD. By the time these potential recipients present
for evaluation, their own siblings often have PKD and obviously
can't donate, and their children are at an age, usually early
twenties, when it's too early to tell whether they also will develop
PKD. What test should we use, and how early can it be used, to
establish whether a young potential donor is disease-free? Lately
we've been using high-resolution CT for potential donors in their
mid-20s. Usually we don't do gene testing because the families
can't or don't want to pay for it.
DR. PERR0NE: Ultrasound has been extensively evaluated for
use as a diagnostic tool for ADPKD linked to chromosome 16.
The criterion of bilateral renal cysts with at least two in one kidney
was critically examined by Ravine and coworkers in 128 sibships
within 18 PKD1 families [120]. Because the prevalence of simple
cysts in the nonaffected population rises with age, this criterion is
less specific in older patients. These workers suggested that at
least two renal cysts (unilateral or bilateral) in individuals at risk
and younger than 30 years of age was sufficient to make a
diagnosis; from age 30 to 59, the presence of at least two cysts per
kidney was sufficient; and from age 60 and above, at least four
cysts in each kidney is required to make the diagnosis [120].
DR. HARRINGTON: At what probability level?
DR. PERRONE: The positive and negative predictive values,
respectively, using the criteria from Ravine's group, are as follows:
for individuals under age 30, positive predictive value (PPV),
99.2%; negative predictive value (NPV), 100%; for individuals
aged 20—59, PPV, 100%; NPV, 100%; and for individuals 60 and
older, PPV, 97%—l00%; and NPV, 100%. In the form linked to
chromosome 4, the cysts appear at a later age. These studies have
not been repeated using high resolution CT or MRI imaging.
Linkage studies, if you have enough affected (at least 2) and
unaffected family members, are most informative. That's the best
way to be certain in particular cases.
DR. HARRINCTON: Recently I had a patient with polycystic
kidney disease who received a renal transplant. A week or so after
transplantation, the patient had a cecal perforation. How often do
you see cecal perforation or diverticular blow-out in the immedi-
ate postoperative setting in patients with PKD?
DR. PERRONE: The majority of colonic perforations occur within
three months after transplantation [12 1—123]. The eases of AD-
PKD reported in these series do not appear to exhibit a different
clinical course. The earliest reported perforation that I could find
in a patient with ADPKD was 21 days after transplantation [123].
DR. EDWARD WALSHE: (Renal Fellow, Division of Nephrology,
New England Medical Center): Is there a higher rate of complica-
tions, particularly vascular ones, after transplantation?
DR. PERRONE: Most studies indicate that patients with or
without ADPKD have similar graft and patient survival after renal
transplantation. Infectious complications predominate early in the
post-transplant course, whereas cardiovascular complications are
more significant over the long term [1241. In a recent study,
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cardiovascular mortality was greater in ADPKD than in non-
ADPKD, non-diabetic transplant recipients who received azathio-
prine [125]; the difference was not significant for cyclosporine-
treated transplant recipients.
DR. WALSHE: What about aneurysms?
DR. PERRONE: Several series document isolated occurrences of
post-transplant rupture or symptoms attributable to intracranial
aneurysm in ADPKD patients [95, 124]. In general, transplanta-
tion does not appear to increase the risk of intracranial aneurysm
expansion or rupture in patients with ADPKD [126].
DR. NIcoLAos ATHIENITES (Division of Nephrology, New England
Medical Center): Are there histologic differences between the type
of aneurysm found in PKD patients and the type found in patients
with essential hypertension? Are there any differences either in
the collagen structure or in the extracellular matrix between the
former and the latter groups?
DR. PERRONE: That's a good question because it relates to how
the aneurysm is initiated. Intracranial aneurysms in ADPKD are
typical saccular or "berry" aneurysms. To my knowledge, there
have been no biochemical or molecular studies of the extracellular
matrix of intracranial aneurysms in ADPKD. Polycystin is ex-
pressed in the myocytes of elastic and large distributive arteries
including ICA and tends to be higher in ADPKD versus control
ICA [47].
DR. PAUL PRONOVOST (Renal Fellow, Division of Nephrology,
New England Medical Center): My question is similar to that of
several others, Specifically, what do you recommend to your
patients with ADPKD when they want their offspring screened for
the disease, given the current climate and health care policies in
the United States regarding insurability?
DR. HARRINGTON: I tell them never to be screened.
DR. PERRONE: The issue about screening is really based on
whether or not you would do anything that would help the patient.
That is, if you screened them and found they had the disease and
you could offer them a specific treatment, I'd say go ahead.
Because of the potentially negative repercussions for insurability
and future employment, I would avoid it. If you think about it,
what can you do for them? You can treat hypertension without
knowing whether they have cysts in their kidneys. On the other
hand, should hematuria be detected or urinary tract infection
develop, the detection of renal cysts would have an impact on
clinical management. I would follow the urinalysis and blood
pressure closely in a patient at risk for inheriting ADPKD.
DR. PRoNovosT: Would you advise patients against screening?
DR. PERRONE: Not necessarily. I would inform them of the pros
and cons so as to enable them to select the best course for each
individual.
DR. LINsHAw: Is there any blood abnormality that might give
you a clue that hepatic cysts are present before they're big enough
to see?
DR. PERRONE: No, liver function tests are usually normal in an
ADPKD patient with hepatic cysts. Ultrasound examination or
high-resolution computed tomography are the best ways to find
liver cysts. I'm not aware of any clinical clues other than pain.
Reprint requests to: Dr. R. Perrone, New England Medical Center, Division
of Nephrology, Box 172, 750 Washington Street, Boston, Massachusetts, USA
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